Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen

Immix Biopharma (NASDAQ:IMMX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other research analysts have also recently weighed in on IMMX. Mizuho started coverage on shares of Immix Biopharma in a research note on Monday, February 9th. They set an “outperform” rating and a $14.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.00.

Immix Biopharma Price Performance

NASDAQ IMMX opened at $9.29 on Friday. The stock has a market capitalization of $492.00 million, a price-to-earnings ratio of -12.06 and a beta of 0.25. Immix Biopharma has a 1-year low of $1.34 and a 1-year high of $9.47. The business’s fifty day moving average price is $6.38 and its 200-day moving average price is $4.47.

Institutional Trading of Immix Biopharma

A number of large investors have recently added to or reduced their stakes in IMMX. Barclays PLC purchased a new stake in shares of Immix Biopharma in the fourth quarter valued at $183,000. Jump Financial LLC purchased a new position in shares of Immix Biopharma during the 4th quarter worth about $177,000. Hudson Bay Capital Management LP purchased a new position in shares of Immix Biopharma during the 4th quarter worth about $176,000. Persistent Asset Partners Ltd bought a new position in Immix Biopharma during the 4th quarter valued at about $166,000. Finally, United Capital Financial Advisors LLC bought a new position in Immix Biopharma during the 3rd quarter valued at about $148,000. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.